Formulation Development and Evaluation of Ondansetron Microsponges for Topical Application
DOI:
https://doi.org/10.53555/bp.v3i5.129Keywords:
Ondansetron, Microsponge, Gel, Eudragit RS 100, Carbopol 940, chemotherapyAbstract
The main aim of the study is to develop microsponges of ondansetron, microsponges are polymeric delivery systems composed of porous microspheres. These are tiny-sponge like spherical particles with a large porous surface. These may enhance stability, reduce side effects. Microsponge drug delivery system is a versatile drug delivery vehicle because of its favorable characteristics. Microsponges are designed to deliver a pharmaceutical active ingredient efficiently at the minimum dose and to enhance stability, reduce side effects and modify drug release. Ondansetron is a highly specific selective serotonin 5-HT3 receptor antagonist having no activity at other serotonin receptors and low affinity for dopamine receptors. Nausea and vomiting are some of the major side effect caused by certain drug therapies like chemotherapy, radiotherapy, post-operation and radiation. Due to these symptoms, oral administration is inappropriate and intravenous administration may be unpractical. So to overcome these ondansetron microsponges for topical application were developed using various drug: polymer ratios (ondansetron : Eudragit RS100) as 2:1, 4:1, 6:1, 8:1, 10:1 and 12:1 keeping stirrer rate at 600 rpm constant. The formulations were studied for drug entrapment estimation, production yield and physical characterization. The physical characterization showed that microsponges formulated showed
reproducible results. Then the six microsponge formulations prepared as gel by using Carbopol 940, and all the gels were evaluated for their appearance, pH, drug content, rheological properties and in-vitro release. The compatibility studies were carried out using Fourier transform infra-red spectroscopy. The viscosity of all formulated ondansetron gels found in range of 3025 to 4042 cps.
pH 6.1-6.4. Drug content of all prepared formulations found in the range of 92.8-93.8%, and
percentage drug content showed satisfactory. Among all those F6 shows maximum drug release.
The invitro drug release studies were done and best fit model was found to be zero order indicating
drug release is independent upon concentration. The n value > 0.5 suggests that the drug released
non-fickian release mechanism, i.e. drug released by erosion followed by diffusion controlled.
Downloads
References
Chowdary KPR, Rao YS. Mucoadhesive Microspheres for Controlled Drug Delivery. Biol Pharm Bull 2004;27(11):1717-1724.
Nacht S, Kantz M. (1992), The Microsponge: A Novel Topical Programmable Delivery System. Chapter 15, In: Topical Drug Delivery Systems. Edited by David W. O. and Anfon H. A. Volume 42, pp 299-325.
Martin A, Swarbrick J,Cammarrata A.(1991) Chapter 19, In: Physical Pharmacy-Physical Chemical Principles in Pharmaceutical Sciences. 3rd Ed., pp 527.
Shah VP. Determination of In-vitroRelease from Hydrocortisone Creams. Int J Pharm 1989; 53: 53-59. 61
Jain V, Singh R. Dicyclomine loaded Eudragit based Microsponge with Potential for Colonic Delivery Preparation and Characterization. Trop Jour Pharma Res.2010; 9 (1): 67-72.
Amrutiya N, Bajaj A, Madan M.Development of Microsponges for Topical Delivery of Mupirocin. AAPS PharmSciTech 2009; 10(2):402-409.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 gnpublication@
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
In consideration of the journal, Green Publication taking action in reviewing and editing our manuscript, the authors undersigned hereby transfer, assign, or otherwise convey all copyright ownership to the Editorial Office of the Green Publication in the event that such work is published in the journal. Such conveyance covers any product that may derive from the published journal, whether print or electronic. Green Publication shall have the right to register copyright to the Article in its name as claimant, whether separately
or as part of the journal issue or other medium in which the Article is included.
By signing this Agreement, the author(s), and in the case of a Work Made For Hire, the employer, jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere, and is not being considered for publication elsewhere in any form, except as provided herein. Each author’s signature should appear below. The signing author(s) (and, in
